Logotype for Chiron Real Estate Inc

Chiron Real Estate (XRN) Q2 2024 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Chiron Real Estate Inc

Q2 2024 earnings summary

2 Feb, 2026

Executive summary

  • Portfolio occupancy at quarter end was 96.2% with a weighted average lease term of 5.8 years and average rent coverage ratio of 4.6x.

  • Net loss attributable to common shareholders was $3.1 million ($0.05 per share) for Q2 2024, compared to net income of $11.8 million ($0.18 per share) in Q2 2023, mainly due to a $3.4 million loss on property sale.

  • FFO was $13.9 million ($0.20 per share/unit), AFFO was $15.7 million ($0.22 per share/unit), both down slightly year-over-year.

  • Acquisition of a 15-property outpatient medical real estate portfolio for $80.3 million at an 8% cap rate, with the first tranche of 5 properties ($30.8 million) closed post-quarter and the remaining 10 properties ($49.5 million) expected to close in Q4 2024.

  • Dispositions included sales in Indiana ($8.1 million) and Florida ($11 million), as part of asset recycling, with one sale resulting in a $3.4 million loss.

Financial highlights

  • Total revenues for Q2 2024 were $34.2 million, down 6% year-over-year, primarily due to 2023 dispositions and $800,000 in rent reserves related to Steward Health Care.

  • Total expenses decreased to $32.8 million from $35 million, driven by lower interest expense and completed dispositions.

  • Interest expense was $7 million, down from $8.5 million in Q2 2023, reflecting lower leverage and effective interest rate swaps.

  • G&A expenses were $4.6 million, up slightly due to higher non-cash LTIP compensation.

  • Adjusted EBITDAre for Q2 2024 was $24.0 million, down from $26.1 million in Q2 2023.

Outlook and guidance

  • Projected occupancy to remain steady at or above 96% for the remainder of 2024.

  • G&A expenses expected to be $4.4–$4.6 million per quarter in the second half of 2024.

  • Full-year 2024 capital expenditures projected at $11–$13 million.

  • Investment pipeline of $120 million in medical office assets, not including the second tranche of the 15-property portfolio, with targeted cap rates in the high 8% to 9% range.

  • Expect to complete the acquisition of the remaining 10 properties in the 15-property portfolio in Q4 2024, subject to customary conditions.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more